Wuxi Biologics (Cayman) (2269) Stock Forecast & Price Target

Compare

52 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2269 Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Wuxi

Biologics (Cayman)

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2269 Stock 12 Month Forecast

Average Price Target

HK$42.17

▲(31.52% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Wuxi Biologics (Cayman) in the last 3 months. The average price target is HK$42.17 with a high forecast of HK$50.00 and a low forecast of HK$33.50. The average price target represents a 31.52% change from the last price of HK$32.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","30":"HK$30","51":"HK$51","19.5":"HK$19.5","40.5":"HK$40.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50.001944928,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.1661908,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$42.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.50130310176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$33.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,19.5,30,40.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.2,37.26168807138462,38.323376142769234,39.38506421415385,40.446752285538466,41.50844035692308,42.5701284283077,43.631816499692306,44.69350457107693,45.75519264246154,46.81688071384616,47.87856878523077,48.940256856615385,{"y":50.001944928,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.2,36.65893775384615,37.11787550769231,37.57681326153846,38.03575101538462,38.49468876923077,38.95362652307693,39.41256427692308,39.871502030769236,40.330439784615386,40.789377538461544,41.248315292307694,41.70725304615385,{"y":42.1661908,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.2,35.99240793090462,35.784815861809236,35.57722379271385,35.36963172361846,35.16203965452308,34.954447585427694,34.74685551633231,34.53926344723693,34.33167137814154,34.12407930904615,33.91648723995077,33.708895170855385,{"y":33.50130310176,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$50.00

Average Price TargetHK$42.17

Lowest Price TargetHK$33.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jialin Zhang

Nomura

HK$37.36

Buy

16.53%

Upside

Reiterated

11/28/25

Laurence Tam

Morgan Stanley

HK$35→HK$45

Buy

40.36%

Upside

Reiterated

11/20/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ziyi Chen

Goldman Sachs

HK$29.3→HK$33.5

Hold

4.49%

Upside

Reiterated

10/17/25

Goldman Sachs Keeps Their Hold Rating on Wuxi Biologics (Cayman) (WXIBF)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

HK$50

Buy

55.96%

Upside

Reiterated

10/08/25

Linda Shu

HSBC

HK$37.5→HK$45

Buy

40.36%

Upside

Reiterated

09/26/25

HSBC Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)

Tony Ren

Macquarie

HK$40

Buy

24.77%

Upside

Reiterated

09/08/25

Macquarie Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)

Chen Chen

UBS

HK$42.3→HK$46.9

Buy

46.29%

Upside

Reiterated

09/03/25

UBS Reaffirms Their Buy Rating on Wuxi Biologics (Cayman) (WXIBF)

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$48.18

Buy

50.28%

Upside

Reiterated

08/31/25

Nico Chen

DBS

HK$23.4→HK$36

Hold

12.29%

Upside

Reiterated

08/26/25

DBS Sticks to Their Hold Rating for Wuxi Biologics (Cayman) (WXIBF)

Unknown Analyst

CCB Intl.

Not Ranked

CCB Intl.

HK$39

Buy

21.65%

Upside

Reiterated

08/26/25

Michael Luo CFA

CLSA

HK$34.8→HK$42.6

Buy

32.88%

Upside

Reiterated

08/25/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$48.18

Buy

50.28%

Upside

Reiterated

08/23/25

Yang Huang

J.P. Morgan

HK$36→HK$37

Buy

15.41%

Upside

Reiterated

08/21/25

J.P. Morgan Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)JPMorgan analyst Yang Huang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$37.00 (from HK$36.00) while maintaining a Overweight rating.

Jill Wu

CMB International Securities

HK$35.6

Buy

11.04%

Upside

Reiterated

08/21/25

John Yung

Citi

HK$35→HK$40

Buy

24.77%

Upside

Reiterated

08/21/25

Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from CitiCiti analyst John Yung raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$40.00 (from HK$35.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jialin Zhang

Nomura

HK$37.36

Buy

16.53%

Upside

Reiterated

11/28/25

Laurence Tam

Morgan Stanley

HK$35→HK$45

Buy

40.36%

Upside

Reiterated

11/20/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ziyi Chen

Goldman Sachs

HK$29.3→HK$33.5

Hold

4.49%

Upside

Reiterated

10/17/25

Goldman Sachs Keeps Their Hold Rating on Wuxi Biologics (Cayman) (WXIBF)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

HK$50

Buy

55.96%

Upside

Reiterated

10/08/25

Linda Shu

HSBC

HK$37.5→HK$45

Buy

40.36%

Upside

Reiterated

09/26/25

HSBC Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)

Tony Ren

Macquarie

HK$40

Buy

24.77%

Upside

Reiterated

09/08/25

Macquarie Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)

Chen Chen

UBS

HK$42.3→HK$46.9

Buy

46.29%

Upside

Reiterated

09/03/25

UBS Reaffirms Their Buy Rating on Wuxi Biologics (Cayman) (WXIBF)

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$48.18

Buy

50.28%

Upside

Reiterated

08/31/25

Nico Chen

DBS

HK$23.4→HK$36

Hold

12.29%

Upside

Reiterated

08/26/25

DBS Sticks to Their Hold Rating for Wuxi Biologics (Cayman) (WXIBF)

Unknown Analyst

CCB Intl.

Not Ranked

CCB Intl.

HK$39

Buy

21.65%

Upside

Reiterated

08/26/25

Michael Luo CFA

CLSA

HK$34.8→HK$42.6

Buy

32.88%

Upside

Reiterated

08/25/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$48.18

Buy

50.28%

Upside

Reiterated

08/23/25

Yang Huang

J.P. Morgan

HK$36→HK$37

Buy

15.41%

Upside

Reiterated

08/21/25

Jill Wu

CMB International Securities

HK$35.6

Buy

11.04%

Upside

Reiterated

08/21/25

John Yung

Citi

HK$35→HK$40

Buy

24.77%

Upside

Reiterated

08/21/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wuxi Biologics (Cayman)

1 Month

xxx

Success Rate

3/3 ratings generated profit

Average Return

+8.57%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +8.57% per trade.

3 Months

xxx

Success Rate

6/8 ratings generated profit

Average Return

+13.69%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +13.69% per trade.

1 Year

Yang HuangJ.P. Morgan

Success Rate

4/4 ratings generated profit

Average Return

+42.15%

reiterated a buy rating 4 months ago

Copying Yang Huang's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +42.15% per trade.

2 Years

xxx

Success Rate

4/4 ratings generated profit

Average Return

+42.15%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +42.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2269 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2269 has received 7 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 2269 average Analyst price target in the past 3 months is 42.17.

Each month's total comprises the sum of three months' worth of ratings.

2269 Financial Forecast

2269 Earnings Forecast

Next quarter’s earnings estimate for 2269 is HK$0.62 with a range of HK$0.62 to HK$0.62. The previous quarter’s EPS was HK$0.61. 2269 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 2269 has Performed in-line its overall industry.

2269 Sales Forecast

Next quarter’s sales forecast for 2269 is HK$12.86B with a range of HK$12.86B to HK$12.86B. The previous quarter’s sales results were HK$10.69B. 2269 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 2269 has Performed in-line its overall industry.

2269 Stock Forecast FAQ

What is HK:2269’s average 12-month price target, according to analysts?

Based on analyst ratings, Wuxi Biologics (Cayman) Inc.’s 12-month average price target is 42.17.

What is HK:2269’s upside potential, based on the analysts’ average price target?

Wuxi Biologics (Cayman) Inc. has 31.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Wuxi Biologics (Cayman) Inc. a Buy, Sell or Hold?

Wuxi Biologics (Cayman) Inc. has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Wuxi Biologics (Cayman) Inc.’s share price target?

The average share price target for Wuxi Biologics (Cayman) Inc. is 42.17. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$50.00 ,and the lowest forecast is HK$33.50. The average share price target represents 31.52% Increase from the current price of HK$32.06.

What do analysts say about Wuxi Biologics (Cayman) Inc.?

Wuxi Biologics (Cayman) Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Wuxi Biologics (Cayman) Inc.?

To buy shares of HK:2269, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Wuxi Biologics (Cayman) (2269) Stock Forecast & Price Target

2269 Analyst Ratings

2269 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Wuxi Biologics (Cayman)

2269 Analyst Recommendation Trends

2269 Financial Forecast

2269 Earnings Forecast

2269 Sales Forecast

2269 Stock Forecast FAQ

Detailed List of Analyst Forecasts